Sanofi — Director's Dealing 2016

Jan 14, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: REGENERON PHARMACEUTICALS INC (REGN)
CIK: 0000872589
Period of Report: 2016-01-12

Reporting Person: Sanofi (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-01-12	Common Stock	P	5007	$453.8912	Acquired	23113577	Indirect
2016-01-12	Common Stock	P	2407	$454.5971	Acquired	23115984	Indirect
2016-01-12	Common Stock	P	2164	$455.6774	Acquired	23118148	Indirect
2016-01-12	Common Stock	P	3220	$457.1844	Acquired	23121368	Indirect
2016-01-12	Common Stock	P	3100	$457.9952	Acquired	23124468	Indirect
2016-01-12	Common Stock	P	2500	$460.1156	Acquired	23126968	Indirect
2016-01-12	Common Stock	P	3563	$461.4128	Acquired	23130531	Indirect
2016-01-12	Common Stock	P	4941	$462.2263	Acquired	23135472	Indirect
2016-01-12	Common Stock	P	2759	$463.1723	Acquired	23138231	Indirect
2016-01-12	Common Stock	P	4148	$464.4110	Acquired	23142379	Indirect
2016-01-12	Common Stock	P	8002	$465.4998	Acquired	23150381	Indirect
2016-01-12	Common Stock	P	3608	$466.2618	Acquired	23153989	Indirect
2016-01-12	Common Stock	P	4901	$467.6617	Acquired	23158890	Indirect
2016-01-12	Common Stock	P	5082	$468.4646	Acquired	23163972	Indirect
2016-01-12	Common Stock	P	14169	$469.7058	Acquired	23178141	Indirect
2016-01-12	Common Stock	P	7204	$470.6444	Acquired	23185345	Indirect
2016-01-12	Common Stock	P	3600	$471.5617	Acquired	23188945	Indirect
2016-01-12	Common Stock	P	3563	$472.6410	Acquired	23192508	Indirect

Footnotes

F1: The number of securities reported represents an aggregate number of shares purchased in multiple market transactions over a range of purchase prices. The price reported represents the weighted average price per share. The Reporting Person undertakes to provide the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range.

F2: Represents shares acquired directly by sanofi-aventis Amerique du Nord ("SAAN").

F3: Purchase prices range from $453.09 to $454.07 per share, inclusive.

F4: Indirectly owned through (a) SAAN, a direct, wholly-owned subsidiary of Sanofi, and (b) Aventis Pharmaceuticals Inc. ("Aventis"), an indirect, wholly-owned subsidiary of SAAN. After giving effect to all acquisitions reported on this Form 4, the number of shares beneficially owned directly by SAAN and Aventis was 20,392,956 shares and 2,799,552 shares, respectively. Pursuant to the Amended and Restated Investor Agreement, dated as of January 11, 2014, by and among Sanofi, SAAN, sanofi-aventis US LLC, Aventis (collectively, the "Sanofi Parties") and the Issuer, the Sanofi Parties have agreed to vote their respective shares of the Issuer, subject to specified exceptions, in accordance with the recommendation of the Issuer's Board of Directors.

F5: Purchase prices range from $454.21 to $455.19 per share, inclusive.

F6: Purchase prices range from $455.24 to $456.19 per share, inclusive.

F7: Purchase prices range from $456.59 to $457.54 per share, inclusive.

F8: Purchase prices range from $457.60 to $458.41 per share, inclusive.

F9: Purchase prices range from $459.64 to $460.52 per share, inclusive.

F10: Purchase prices range from $460.71 to $461.66 per share, inclusive.

F11: Purchase prices range from $461.73 to $462.71 per share, inclusive.

F12: Purchase prices range from $462.83 to $463.46 per share, inclusive.

F13: Purchase prices range from $463.96 to $464.92 per share, inclusive.

F14: Purchase prices range from $464.99 to $465.93 per share, inclusive.

F15: Purchase prices range from $465.99 to $466.97 per share, inclusive.

F16: Purchase prices range from $466.99 to $467.94 per share, inclusive.

F17: Purchase prices range from $468.09 to $468.87 per share, inclusive.

F18: Purchase prices range from $469.11 to $470.10 per share, inclusive.

F19: Purchase prices range from $470.11 to $471.10 per share, inclusive.

F20: Purchase prices range from $471.14 to $471.92 per share, inclusive.

F21: Purchase prices range from $472.31 to $473.23 per share, inclusive.